The actual link to the zoom seminar registration page:
2 Likes
When we get to see the results it feels like it’s first page news on Rapamycin.news 
4 Likes
Agetron
#85
Thanks for the ZOOM link.
Just signed up.
Will enjoy hearing everything that Matt Kaeberlein has to say… he’s my rock star.
3 Likes
Jonas
#86
So based on this https://www.medrxiv.org/content/10.1101/2024.08.21.24312372v1
5mg is too low a dose to have effect? visceral fat loss for super-responders?
Also "the most robust improvements in lean tissue mass in women taking 10 mg rapamycin/week"
Perfectly in line with the ITP results.
Note the distinction between generic tablets and pill or capsules from a compounding pharmacy. There is reason to believe the compounded product is less potent at the same weight.
1 Like
Jonas
#89
Anyone remember how they dosed the 10mg? IIRC, it was divided in two doses?
Edit: the following are the dosing regimen:
1 Like
Here is my first comment on the trial. I will write a more deeper post later on.
Really great work with getting the results published as a preprint! It’s lots of hard work behind so big thumbs up for that! I will write down more of my thoughts around the trial after the PEARL trial webinar on 27th of August. The probably most important thing to point out in this trial to begin with is that it’s a very low dosing. The highest dosing schedule which is 10 mg/weekly is equivalent to around 3 mg/weekly of generic rapamycin. It’s few males that take such low doses of Rapamycin but I know there are females who take that dose. Females mice as you mentioned seem to respond better on low doses than male mice. This has also been seen in the ITP where the lowest dose of Rapamycin tested was 4.7ppm and the result was median lifespan 17% in females and 3% in males and maximum lifespan 14% in females and 6% in males (pubmed: 22587563).
It’s really great also that we now have even more data on that Rapamycin is well tolerated even if it’s on very low doses. This trial is a very important milestone in the field and step by step more data will come from AgelessRx. One thing I really like with that longevity clinic is that they try to push longevity research forward and they are not afraid of sharing the data. So more clinics should inspire from this approach and by that we increase the chances of living a longer and healthier life!
Source: x.com
7 Likes
Melih
#91
Could anyone explain why the 5mg dose in males performed worse than the placebo, specifically BMC?
Females saw no increase in BMC (even at 10mg compounded), is it because they lack their youthful estrogen levels? All women were post-menopausal.
Authors on their dose:
Alot of the weirder results in this study can likely be explained by the simple fact that the dose was too low to have a noticeable effect, and that differences are just due to random fluctuations. The ”high dose” group was only taking 3 mg rapamycin per week, and the low dose group was taking 1,5 mg.
Apart from that, they’ve looked at a bazillion different outcomes. When you do that, you can’t use a p-value of 0,05 for significance, because you’ll get lots of false positive results. You need to use a much stricter value for statistical significance, say 0,0005. But then, with the study having so few participants, you’ll get lots of false negatives instead. Basically, the design of the study is flawed, and constructed in a way that makes it pretty much impossible to draw any meaningful conclusions, and it doesn’t add much to our understanding of rapamycin as an anti-aging drug.
8 Likes
Pat25
#93
Does anyone happen to know how the ‘compounded’ Rapamycin was formulated/what its composition is?
AnUser
#94
Looks like the CI’s are below/above 0 for placebo, which means it wasn’t statistically significant and thus you can’t really compare them.
For larger trials we need someone like Tornado Therapeutics.
It is not enteric coated so it is broken down by stomach acid, lowering bioavailability, as far as I know.
3 Likes
It is such a pity that they used compounded Rapamycin without coating. What a missed opportunity. Had they simply looked at serum levels, it would have likely been noted that the 10 mg was barely making a blip on levels as compared to coated commercially available tablets.
So we essentially learn nothing from this trial, as the effective dose I take is massively more, so further data on safety beyond Dr. K’s review of this isn’t expanded.
We also have no idea on benefits with the way that most of us are taking Rapamycin, given what will be effectively 2.5-3 mg of Rapamycin weekly in the 10 mg group.
Maybe I’m missing something, but it seems like this is a huge letdown and gives us no insight into the questions it was meant to answer due to use of compounded rapamycin.
9 Likes
AnUser
#96
That’s pretty close to the 5 mg dose that’s typically recommended per week though? Okay it’s almost double the amount, but still, it’s not like a microdose.
For me I’m usually taking 10-12 mg every 9 days… so what I’m doing is based on serum levels to a target. This study doesn’t inform me of anything as the effective doses given were very low.
2 Likes
AnUser
#98
For what it’s worth, 0.5 mg everolimus every day was as effective as 5 mg / 10 mg once a week in the 2014 Mannick trial if I remember correctly. That’s 3.5 mg a week. The 10 mg once a week didn’t even work so well IIRC.
Yes - a rather disappointing outcome given the potential for this study, and the very low number of healthy human studies we have. This study will not add much to the argument for rapamycin.
7 Likes
adriank
#101
What is your serum target?
